EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Efficacy of Dupilumab in Patients From China With Persistent Type 2 Asthma With and Without an Allergic Phenotype

Qingling Zhang iD, Zhenan Deng iD, Xiuhua Fu, Haohui Fang, Jie Lin iD, Jérôme Msihid iD, Yvonne Huang, Jason H Kwah, Olivier Ledanois iD, Nanshan Zhong iD

Clinical & Experimental Allergy · 04.11.2026

DOI: 10.1111/cea.70462 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical & Experimental Allergy, online erschienen am 04.11.2026. Verfasst von Qingling Zhang und 9 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Respiratory Disease, Department of Pulmonary and Critical Care Medicine, National Clinical Research Center for Respiratory Di…. Die Arbeit nennt 8 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Sanofi, Regeneron Pharmaceuticals.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Asthma is underdiagnosed and undertreated in China, where treatment with dupilumab could be beneficial. In this industry‐funded post hoc exploratory analysis, dupilumab showed clinical efficacy in allergic and non‐allergic asthma.

Schlagwörter

Stichwörter der Autor:innen

Chinaallergic phenotypeasthma control and quality of lifeexacerbationslung functionmoderate‐to‐severe asthmatype 2 inflammation

Autor:innen und Institutionen

  • State Key Laboratory of Respiratory Disease, Department of Pulmonary and Critical Care Medicine, National Clinical Research Center for Respiratory Disease, National Center for Respiratory Medicine, Guangzhou Institute o…
  • Guangzhou National Laboratory, Bioland, Guangzhou, China.
  • The Affiliated Hospital of Inner Mongolia Medical University, Hohhot, China.
  • Anhui Chest Hospital, Hefei, China.
  • The Second Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
  • Sanofi, Gentilly, France.

ORCID-Profile: Qingling Zhang, Zhenan Deng, Jie Lin, Jérôme Msihid, Olivier Ledanois, Nanshan Zhong

Förderung

  • Sanofi
  • Regeneron Pharmaceuticals

Zitieren

APA

Zhang, Q., Deng, Z., Fu, X., Fang, H., Lin, J., Msihid, J., Huang, Y., Kwah, J. H., Ledanois, O., & Zhong, N. (2026). Efficacy of Dupilumab in Patients From China With Persistent Type 2 Asthma With and Without an Allergic Phenotype. Clinical & Experimental Allergy. https://doi.org/10.1111/cea.70462

Vancouver

Zhang Q, Deng Z, Fu X, Fang H, Lin J, Msihid J, et al. Efficacy of Dupilumab in Patients From China With Persistent Type 2 Asthma With and Without an Allergic Phenotype. Clinical & Experimental Allergy. 2026. doi:10.1111/cea.70462

BibTeX
@article{Zhang2026,
  author = {Zhang, Qingling and Deng, Zhenan and Fu, Xiuhua and Fang, Haohui and Lin, Jie and Msihid, Jérôme and Huang, Yvonne and Kwah, Jason H and Ledanois, Olivier and Zhong, Nanshan},
  title = {Efficacy of Dupilumab in Patients From China With Persistent Type 2 Asthma With and Without an Allergic Phenotype},
  journal = {Clinical & Experimental Allergy},
  year = {2026},
  doi = {10.1111/cea.70462}
}
Kostenlos starten →